Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration

Xanthos, Theodoros; Bassiakou, Eleni; Vlachos, Ioannis S.; Bassiakos, Sotirios; Michalakis, Konstantinos; Moutzouris, Dimitris-Anestis; Papadimitriou, L.

doi:10.1016/j.ijcard.2007.02.024

Cited by 15 publications

(23 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with prior studies which have shown large differences in cardioversion speed between antiarrhythmic agents [48]. Among the 6 antiarrhythmics assessed here, amiodarone is thought to be the slowest to act, with mean or median cardioversion times in the range of 8-12 h. [48,49,50] Procainamide has a median time to cardioversion of 3 h [48], while propafenone (IV) and flecainide (IV) have mean or median times to cardioversion in the range of 14-22 min. [51,52] Vernakalant appears to be modestly quicker, with median times in the range of 8-11 min.…”

Section: Discussionsupporting

confidence: 90%

“…[38,41] While rapid cardioversion seems to translate to shorter length of hospital stay, with patients successfully cardioverting on vernakalant spending, on average, 30.8 h between admission and discharge [53], treatment-specific data on length of hospital stay among comparators is sparse. 1 It should be noted that the higher odds ratio of 33.26 for vernakalant versus placebo was dictated by odds ratios from 3 individual studies of vernakalant versus placebo [41,44,50] as well as an indirect comparison derived from a study of vernakalant versus amiodarone [40]. Odds ratios for the 3 direct comparisons of vernakalant versus placebo ranged from 24 to 28, while a vernakalant versus amiodarone odds ratio of 19 and amiodarone versus placebo odds ratio of 1.9 in the fourth study corresponded to an indirect vernakalant versus placebo odds ratio of 37.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation

Bash

Buono

Davies

et al. 2012

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

In pair-wise comparisons of active treatment arms to one another, results suggest vernakalant IV, propafenone IV and flecainide appear to be effective in achieving rapid cardioversion in patients with short duration AF compared to other agents. Application of these findings to clinical practice need to account for the variable comorbidity profiles of patients, important determinants in the selection of appropriate therapy for individual patients. Though best practice methods were used, further research comparing treatments through direct head-to-head comparisons may be warranted to confirm these findings and further inform clinical practice.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation

Bash

Buono

Davies

et al. 2012

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…A similar rate of conversions (~85%) with a longer time-to-efficacy (20 versus 12 h) compared to intravenous administration was showed in a recent study [69].…”

Section: Amiodaronesupporting

confidence: 73%

Antiarrhythmic drugs for atrial fibrillation

Marinelli¹,

Capucci²

2011

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

AADs remain fundamental in the acute and long-term management of AF, to control symptoms and to reduce the negative impact of the arrhythmia on QoL. The choice of a rate- over rhythm-control strategy should be individualized and based on accurate evaluation of patient medical history and symptoms. New agents will contribute to improve treatment efficacy together with the guarantee of better safety profiles.

show abstract

“…All the studies selected (12,(15)(16)(17)(18)(19)(20)(21)(22) relate the intravenous administration of amiodarone when performed peripherally to the occurrence of chemical phlebitis and thrombophlebitis. T, et al (22) Am J One of them highlights that just the administration of the bolus of the amiodarone is able to increase the above mentioned complications (15) .…”

Section: Resultsmentioning

confidence: 99%

Assistance algorithm of nursing for amiodarone intravenous infusion

Oliveira¹,

Paes²,

Mesquita³

et al. 2014

Rev Rene

View full text Add to dashboard Cite

This study aimed at identifying scientific publication on phlebitis caused by amiodarone and proposes a nursing care algorithm for interventions in intravenous amiodarone administration grounded in the Infusion Nursing Society and the Center for Disease Control and Prevention. It is a descriptive study mediated by integrative review in MedLine, LILACS, IBECS, BDENF, Cochrane Library and Scielo bases, published from 2006 to 2013. The sample consisted of nine articles. The evidence pointed the incidence of phlebitis due to the infusion of amiodarone and the need to control this event. The algorithm proposed shows the materials to be used and the procedure of drug administration in order to minimize injury. Besides subsidizing the development of future studies, this algorithm also promotes the incorporation of the best recommendation for the interventionist clinical practice.

show abstract

Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration

Cited by 15 publications

References 32 publications

Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation

Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation

Antiarrhythmic drugs for atrial fibrillation

Assistance algorithm of nursing for amiodarone intravenous infusion

Contact Info

Product

Resources

About